The FDA has approved Johnson & Johnson's Tremfya for moderately to severely active Crohn's disease, marking its fourth indication in the US based on robust data from phase III GALAXI and GRAVITI studies.
Eneboparatide, an investigational parathyroid hormone receptor agonist, successfully normalized serum calcium levels and eliminated the need for standard supplementation in adults with chronic hypoparathyroidism at 24 weeks.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.